Clever Leaves and FoliuMed have signed a one-year international supply agreement to bring pharmaceutical-grade bulk cannabis extracts into Germany.
The new supply agreement will see FoliuMed and its German manufacturing partner, Fidelio Healthcare, increase its production using Clever Leaves’ full spectrum THC crude extract, standardised 20 per cent CBD extract and CBD isolate.
Andrés Fajardo, president and incoming CEO of Clever Leaves, commented: “Leveraging our Colombian operation to build and maintain relationships throughout the cannabinoid and pharmaceutical industry is incredibly important to us.
“We’re grateful for the opportunity to expand our international presence by partnering with FoliuMed and Fidelio, bringing Clever Leaves standard of production to a global scale.”
Fidelio aims to utilise Clever Leave’s EU-GMP cannabis to create affordable, orally administered gel capsules prescription medicine for patients in Australia, Europe and Latin America.
FoliuMed CEO, Oliver Zugel, commented: “FoliuMed and our manufacturing partner Fidelio are one of the five producers worldwide who manufacture cannabis soft gels for prescription medicines under EU-GMP.
“We carefully chose Clever Leaves as our preferred raw material supplier for this highly strategic product range. As we are seeing increased customer interest for soft gels, we will expand our range of formulations and are looking forward to work with Clever Leaves in this endeavour.”
The raw material is shipped to FoliuMed’s German operation near Frankfurt where they are processed into soft gels at Fidelio’s EU-GMP contract manufacturing site and will be delivered to a leading Australian customer in the first quarter of 2022.
[activecampaign form=31]
